Exact Sciences Stock, A Cathie Wood’s Play, Surges On Freenome’s Pale Results – Investor’s Business Daily

by

  1. Exact Sciences Stock, A Cathie Wood’s Play, Surges On Freenome’s Pale Results Investor’s Business Daily
  2. Opinion | Too few people are screened for colon cancer. This new test might help. The Washington Post
  3. Freenome Announces Topline Results for PREEMPT CRC® to Validate the First Version of its Blood-Based Test for the Early Detection of Colorectal Cancer PR Newswire
  4. New blood test shows high accuracy for colorectal cancer detection, study finds: ‘Not interchangeable’ Fox News
  5. Citi sees Exact Sciences shares climbing after rival’s data disappoints Investing.com India

Read original article here

Leave a Comment